Eye Care

The Pharmacy Times® Eye Care resource center provides clinical news and articles, coverage from ophthalmology conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?

Medical Marijuana Could Lower Prescription Drug Use

Seventeen states with medical marijuana laws saved Medicare Part D approximately $165.2 million in 2013.

Time-Release Ring Superior to Eye Drops in Glaucoma Patients

Medicated ring shows better adherence rate and decreased eye pressure in patients with glaucoma or ocular hypertension.

Slow-Binding Inhibitors of Cholinesterases Could Lead to New Drugs for Several Diseases

Slow-binding inhibitors of cholinesterases could produce treatments for Alzheimer's disease, myasthenia, and neuroprotection.

Metformin May Reduce Glaucoma Risk in Diabetics

Metformin use is associated with a reduced risk of glaucoma development among diabetics.

EMR Discrepancies May Affect Glaucoma Medication Adherence

Glaucoma patients typically have ever-changing drug therapy regimens involving multiple eye drop products.

New Glaucoma Treatment on Track for FDA Approval

The FDA is reviewing a novel treatment for patients with open angle glaucoma or ocular hypertension.

Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering

Glaucoma: Getting a Clear View

Early detection and treatment are key to protecting eyesight.

The Critical Role of Pharmacists in Management and Adherence of Glaucoma Therapy

This continuing education activity is supported by an unrestricted educational grant from Alcon, Inc.

Generic Glaucoma Medications Enhance Adherence

Switching patients with glaucoma to generic medications can improve their adherence to ophthalmic drug therapies, according to researchers from the University of Michigan Kellogg Eye Center and College of Pharmacy.

Latanoprost Reduces Vision Loss Risk in Glaucoma

Latanoprost eye drops may significantly reduce the risk of vision loss in patients with glaucoma.

Glaucoma Candidate Takes Steps Toward FDA Approval

Latanoprostene bunod (Vesneo) demonstrated noninferiority to timolol maleate (Timoptic 5%) in pivotal Phase 3 studies.

The Pharmacy Times® eye care resource center serves as your one-stop ophthalmology clinic. The content here includes breaking news coverage of approvals from the US Food and Drug Administration, key takeaways from the latest novel therapies in clinical trials, and notifications of updates to clinical guidelines for countless conditions.

Among its other resources are a wealth of videos including interviews with eye care professionals, thought leaders, and experts in the space, as well as moderated Peer Exchange panel discussions about the best practices and key methods for treating complex cases, utilizing the newest therapies, examining the issues and challenges of treating retinal diseases, like achromatopsia, chloridemia, macular degeneration, and others.